Briacell Technologies, Inc., a global leader in the development of novel cancer therapies, is pleased to announce that it has been awarded a grant from the National Cancer Institute (NCI). The grant provides funding to advance Briacell’s Bria-OTS immunotherapy for cancer, a novel tumor-targeting segmentation replacement therapy.
This new grant is part of the NCI’s Small Business Innovation Research (SBIR) program, and is aimed to support the development of innovative cancer treatments to help treat a wide range of types of cancer and improve patient outcomes. The grant is for $ 225,000 and will fund Phase I of Bria-OTS, which is focused on establishing proof-of-concept of the approach and identifying lead trial candidates for Phase 2 clinical trials.
Bria-OTS is a unique and non-invasive approach that utilizes Briacell’s proprietary othomolecular segmentation replacement therapy (OTS) platform to target tumors and modify their immune environments. The platform is highly specific, targeting senescent cancer cells that are resistant to traditional therapies and are believed to drive cancer progression. Once directed to the senescent cancer cells, Bria-OTS is designed to induce a tumor-specific immune response, enhancing the activation of the immune system and enabling it to mount an effective response and fight the disease.
In addition to the NCI grant, Briacell has received more than $ 2 million in funding from the U.S. Department of Defense and the National Institutes of Health. This additional funding will be used to further progress the development of Bria-OTS, with the goal of bringing it to clinical trials and ultimately commercializing the therapy for cancer patients.
Briacell’s Bria-OTS immunotherapy shows promise as a potential treatment for cancer and could significantly improve patients’ outcomes. The grant from the National Cancer Institute is a major step forward for the development of the approach, and the company is looking forward to continuing its research and pushing the boundaries of cancer treatment.
